Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia

ClinicalTrials.gov ID: NCT01977482

Public ClinicalTrials.gov record NCT01977482. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIB, Randomized, Blinded, Dose-ranging, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Dose Response Relationship of GSK1278863 Over the First 4 Weeks of Treatment and Evaluate the Safety and Efficacy of GSK1278863 Over 24 Weeks in Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Switch From Recombinant Human Erythropoietin

Study identification

NCT ID: NCT01977482
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: GlaxoSmithKline; Industry
Enrollment: 216 participants

Conditions and interventions

Conditions

Anaemia

Interventions

GSK1278863 Drug
Placebo Drug
rhEPO Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 99 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 31, 2013
Primary completion: Jan 31, 2015
Completion: Feb 5, 2015
Last update posted: Jun 7, 2018

2013 – 2015

United States locations

U.S. sites: 17
U.S. states: 10
U.S. cities: 16

Facility	City	State	ZIP	Site status
GSK Investigational Site	Azusa	California	91702	—
GSK Investigational Site	Los Angeles	California	90022	—
GSK Investigational Site	Los Angeles	California	90025	—
GSK Investigational Site	San Dimas	California	91773	—
GSK Investigational Site	West Hills	California	91307	—
GSK Investigational Site	Lauderdale Lakes	Florida	33313	—
GSK Investigational Site	Pembroke Pines	Florida	33028	—
GSK Investigational Site	Macon	Georgia	31217	—
GSK Investigational Site	Evergreen Park	Illinois	60805	—
GSK Investigational Site	Bethesda	Maryland	20814	—
GSK Investigational Site	Farmington	Missouri	63640	—
GSK Investigational Site	Amherst	New York	14226	—
GSK Investigational Site	The Bronx	New York	10461	—
GSK Investigational Site	Charlotte	North Carolina	—	—
GSK Investigational Site	Knoxville	Tennessee	37923	—
GSK Investigational Site	San Antonio	Texas	78229	—
GSK Investigational Site	Temple	Texas	76502	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 90 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01977482, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 7, 2018 · Synced Jul 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01977482 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →